Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart ...

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Managed cirrhosis encompasses a wide range of medical interventions and therapeutic strategies aimed at halting disease progression, reducing complications, and enhancing the quality of life of ...

Patients attending Medway Maritime Hospital's A&E will now be routinely tested for HIV and hepatitis unless they opt out. The ...

A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, ...

The "Hepatitis B - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.This report outlays comprehensive insights of present clinical development scenario and ...

Inform people living with hepatitis B of the need to test for hepatitis ... public health officials for greater access to testing, treatment and care.